Personalis
Kar-Mun Wong has extensive work experience in various finance and accounting roles. Kar-Mun currently serves as the VP, Corporate Controller at Personalis, Inc. Prior to this, they held the position of Corporate Controller & Treasurer at Intermedia where they directed treasury and cash management, technical accounting and financial reporting, and corporate and tax compliance functions. Before joining Intermedia, Kar-Mun was a Senior Manager in Accounting Operations at DemandTec, an IBM company, where they played a key role in the merger with IBM and the transition of accounting functions. Kar-Mun also worked at Ernst & Young as a Manager in Advisory Services and as a Senior Accountant, providing financial audit services for various industries. Additionally, Kar-Mun has experience at Charles Schwab as an Internal Auditor, at Cisco as a SOX Consultant, and at San Francisco Coffee as a Country Manager and Regional Finance Manager. Kar-Mun began their career as an Audit Senior at Ernst & Young Singapore, working with clients in the trading and manufacturing industries. Kar-Mun holds an MBA degree.
Kar-Mun Wong earned a Bachelor of Accountancy degree from Nanyang Technological University Singapore in 1996. In 1998, Wong obtained a Master of Science in Finance from University College Dublin. In 2000, Wong completed an MBA in Business Strategy from The University of Western Australia. Wong is also a Certified Public Accountant, certified by the California Board of Accountancy in 2008, and a Chartered Accountant of Singapore, certified by the Institute of Singapore Chartered Accountants in 1999.
This person is not in any teams
Personalis
4 followers
Personalis is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency and quality. Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to the VA Million Veteran Program (MVP). In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis® ImmunoID NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory is GxP-aligned as well as CLIA’88-certified and CAP-accredited.